This technology utilizes butylparaben, commonly known as a preservative, as an active ingredient in pharmaceutical and health functional food compositions for the prevention and treatment of gestational trophoblastic diseases such as hydatidiform mole and chorioadenoma. It also includes methods for inhibiting the proliferation, migration, and invasion of trophoblast cells while promoting apoptosis.
Gestational trophoblastic diseases, such as choriocarcinoma and hydatidiform mole, are caused by the abnormal proliferation, excessive migration, and invasion of trophoblast cells. Choriocarcinoma, in particular, is highly vascular and prone to metastasis to the lungs or vagina. With 15–25% of patients showing resistance to standard chemotherapy and poor prognoses, new treatments are urgently needed; however, the efficacy of butylparaben on trophoblast cells or pregnancy-related diseases has not been previously established.
This technology leverages the ability of butylparaben to inhibit PI3K/AKT and ERK1/2 MAPK signaling within trophoblast cells, thereby preventing cell proliferation and invasion while inducing apoptosis. It also includes formulations combined with targeted inhibitors that address these pathways. Applicable to treatments for hydatidiform mole and chorioadenoma, combination therapies for chemotherapy-resistant trophoblastic tumors, and research reagents, it offers a targeted signaling alternative for patients unresponsive to conventional chemotherapy.
This invention was developed with support from the Ministry of Health and Welfare for the discovery and validation of exosome biomarkers related to early diagnosis, recurrence prediction, and chemotherapy resistance in ovarian cancer based on liquid biopsy.
N/A
